Chen X, Qin S, Gu S, et al. - This multicenter, open-label, phase 2 trial was undertaken to assess camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer (BTC). Untreated advanced BTC patients were administered camrelizumab (3 mg/kg iv gtt, every 2 weeks) plus typical FOLFOX4 (Cam-FOLFOX4 group; infusional 5-fluorouracil, leucovorin and oxaliplatin) or GEMOX (Cam-GEMOX group; infusional gemcitabine and oxaliplatin). The confirmed objective response rate and disease control rate were noted to be 16.3% and 75.0% respectively. A median progression-free survival and overall survival of 5.3 and 12.4 months, respectively, was achieved. Findings demonstrated effectiveness as well as tolerability of camrelizumab plus FOLFOX4 or GEMOX as first-line therapy in Chinese patients with advanced BTC.